metastatic breast cancer news

FDA Expands Approval Of Breast Cancer Drug Kisqali

FDA expands approval of breast cancer drug Kisqali to earlier-stage patients

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.

CNBC on MSN · 2d

Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.

scrippsnews · 1d

Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.

NBC News · 2d

FDA expands approval for drug to treat early-stage breast cancer

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. NBC News' Kathy Park speaks to a woman who took the drug while it was in clinical trials and is now cancer free.

KTSM El Paso on MSN · 1d

FDA expanded their approval on drug cancer drug

First News

oncnursingnews2h

ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

Cure Today21h

Navigating the ‘Ever-Evolving Trajectory’ of Metastatic Breast Cancer

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...

PHILADELPHIA.Today on MSN11h

BriaCell Therapeutics Raises $8.5M After Positive Results for Experimental Cancer Therapy

BriaCell Therapeutics recently closed an $8.5 million stock sale after its positive results from mid-stage testing of its ...

TMCnet3h

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

Medscape2d

Mental Health Considerations in Metastatic Breast Cancer: 5 Things to Know

The high prevalence of depression and anxiety among patients with MBC correlates with diminished survival rates and ...

Targeted Oncology21h

Elacestrant-Abemaciclib Combo Shows Promise for Breast Cancer

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...

The American Journal of Managed Care3d

FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate

1 Ribociclib is manufactured by Novartis for early breast cancer and advanced or metastatic breast cancer. 2 The approval was supported by the NATALEE (NCT03701334) trial, a randomized, open ...

Oncolytics Biotech Reports Favorable Results For Breast Cancer Study

(RTTNews) - Clinical-stage company Oncolytics Biotech Inc. (ONCY), Thursday announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+ ...

Hosted on MSN3d

Novartis’ breast cancer trial of Kisqali reveals 28.5% risk reduction

Kisqali is a selective cyclin-dependent kinase inhibitor that targets proteins involved in the rapid division of cancer cells ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics